PARSIPPANY, N.J.--(BUSINESS WIRE)--Ferring Pharmaceuticals today announced the final 60-month follow-up data from the Phase 3 study of ADSTILADRIN ® (nadofaragene firadenovec-vncg) were presented at ...
Disease-free survival rate of 58% at 12 months (primary endpoint) and 52% at 24 months Cystectomy avoidance rate of 82% at 36 months—unmatched by any product in the field to date Disease-specific ...
The “Get Moving Trial”: A phase I/II RCT of home-based (P)rehabilitation ((P)REHAB) with ExerciseRx in muscle-invasive bladder cancer (MIBC)—Study protocol for a randomized controlled trial. New phase ...
rBCG offers an alternative to TICE® BCG amid U.S. shortages, impacting bladder cancer treatment availability. FDA's Expanded Access Program allows investigational rBCG use when no satisfactory ...
Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window WASHINGTON -- ...
In recent years the management of non-muscle-invasive bladder cancer has undergone radical changes. Intravesical Bacillus Calmette-Guérin (BCG) has long been established as the therapeutic standard ...
HER2 overexpression in patients with nonmuscle-invasive bladder cancer independently predicts worse response to intravesical BCG therapy. HER2 expression can be used to predict outcomes after ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback